OtoNexus Medical Technologies has been awarded a Small Business Innovation Research Phase IIB Grant from the National Science Foundation for its ultrasound platform technology. The OtoNexus platform uses novel ultrasound technology to diagnose middle ear infections in just seconds, providing a non-invasive, rapid, and accurate alternative to current diagnostic methods. The technology is a game-changing solution to diagnosing and managing otitis media, a common childhood illness. The Phase IIB grant recognizes the scientific and technical merit and commercial potential of the OtoNexus technology, placing the company among an elite group of companies chosen to receive extended funding. The Seattle-based medical device company focuses on improving the diagnosis and management of middle ear infections by developing a novel, non-invasive diagnostic platform for this and other medical applications.
OtoNexus Medical Technologies Awarded Prestigious NSF Phase IIB Grant for Ultrasound Platform Technology
OtoNexus Medical Technologies has received a Small Business Innovation Research (SBIR) Phase IIB Grant from the National Science Foundation (NSF) for its ultrasound platform technology. The grant is based on the scientific and technical merit, as well as the commercial potential of the OtoNexus technology, which uses novel ultrasound technology to diagnose middle ear infections in seconds.
Current diagnostic methods are often unreliable and lead to unnecessary antibiotics. However, the OtoNexus platform provides a non-invasive, rapid, and accurate alternative, which simplifies and transforms the evaluation of middle ear infections. This technology provides a game-changing solution to diagnosing and managing otitis media, a common childhood illness, helping healthcare providers to deliver better patient outcomes.
Caitlin Cameron, CEO of OtoNexus, expressed her pride in the company’s achievement, stating that “It is a tremendous honor to receive this grant from the NSF. We are thrilled to have our groundbreaking technology recognized and supported in this way.”
The Phase IIB grant places OtoNexus Medical Technologies among an elite group of companies chosen to receive extended funding. The company is based in Seattle, WA, and focuses on improving the diagnosis and management of middle ear infections by developing a novel, non-invasive diagnostic platform for this and other medical applications. For more information, visit www.otonexus.com.
Key Points:
-
OtoNexus Medical Technologies has received an NSF Phase IIB Grant for its ultrasound platform technology, placing it among an elite group of companies chosen to receive extended funding.
-
The OtoNexus platform provides a non-invasive, rapid, and accurate alternative to current diagnostic methods for middle ear infections, which simplifies and transforms the evaluation of otitis media, a common childhood illness.
-
The technology improves the diagnosis and management of middle ear infections by developing a novel, non-invasive diagnostic platform for this and other medical applications.
-
The company is based in Seattle, WA, and focuses on providing better patient outcomes through its cutting-edge diagnostic platform.
© 2023 Benzinga.com. All rights reserved.
Don’t miss interesting posts on Famousbio
